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INTRODUCTION AND HISTORICAL
BACKGROUND
The concept of the metabolic syndrome has existed
for at least 80 years1. It was first described by Kylin, a
Swedish Physician, as the clustering of hypertension,
hyperglycemia, and gout2. Later, in 1947, Vague drew
attention to upper abdominal adiposity (android or
male-type obesity) as the obesity phenotype that was
commonly associated with type 2 diabetes mellitus and
cardiovascular disease3.
The field moved forward significantly following the
1988 Banting lecture given by Gerald Reaven. He
described a cluster of risk factors for diabetes and
cardiovascular disease comprising hypertension,
hyperglycemia, low high-density lipoprotein (HDL)
cholesterol, and raised very low-density lipoprotein
(VLDL) triglyceride and named it Syndrome X. His
main contribution was the introduction of the concept
of insulin resistance4.
The metabolic syndrome is also known as Syndrome
X, the insulin resistance syndrome, cardio-metabolic
syndrome, dysmetabolic syndrome and the deadly
quartet syndrome5,6 .The constellation include glucose
intolerance (type 2 diabetes, impaired fasting glucose,
or impaired glucose tolerance), insulin resistance, central
obesity, dyslipidemia, and hypertension, all well
documented risk factors for cardiovascular diseases.
The metabolic syndrome is associated with an increased
risk for the development of type 2 diabetes mellitus
and cardiovascular disease. People with the syndrome
are twice as likely to die from a macrovascular event
and three times as likely to have ischemic heart disease
and stroke compared with people without the
syndrome7. The syndrome is affecting the general
population in epidemic proportion and is frequently
associated with increased risk of cardiovascular
morbidity and mortality8,9.










A cluster of risk factors for cardiovascular disease and type 2
diabetes mellitus, which occur together have become known as
the metabolic syndrome. Over the years various diagnostic criteria
have been proposed by different organizations and most recently
efforts have been made to unify the diagnostic criteria. This article
is aimed at providing an overview of  the metabolic syndrome
and a rational approach to the management of  this very important
clinical syndrome.
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Epidemiology
Over the past two decades, a striking increase in the
number of people with the metabolic syndrome
worldwide has taken place. This increase is associated
with the global epidemic of  obesity and diabetes. With
the elevated risk not only of diabetes but also of
cardiovascular disease from the metabolic syndrome,
there is an urgent need for strategies to prevent the
emerging global epidemic10, 11.
In the United States, the metabolic syndrome is
emerging as a major public health problem. Between
1988-1994 and 1999-2000, the age adjusted prevalence
of the metabolic syndrome increased dramatically
among women (23.5%) and only slightly among men
(2.2%). An estimated 55 million adults in the United
States had the syndrome in 2000. The age adjusted
prevalence was 31.9% among Mexican Americans,
23.8% among non-Hispanic whites, and 21.6% among
African Americans12, 13.
The prevalence of the metabolic syndrome among a
multi-ethnic population of 1276 men and women
from four communities in Canada was 25.8% 14. The
prevalence in a population based cohort of 1565
individuals with diabetes in Italy was 75.6% 15. A study
done in Oman showed a prevalence of 23.0% in
women and 19.5% in men16. The prevalence of the
metabolic syndrome among healthy elderly South-
western Nigerians was 35% 17 while a study done in
Benin, Nigeria using three diagnostic tools- World
Health Organization (WHO), Adult Treatment Panel
(ATPIII) and International Diabetes Federation (IDF)
criteria revealed a prevalence of 33.4%, 22.6% and
30.9% respectively18.
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Clinical Diagnosis of Metabolic Syndrome
Many investigations confirm that multiple
cardiovascular risk factors of endogenous origin
commonly aggregate in one individual. Although the
metabolic syndrome is often referred to as a discrete
entity, it is important to recognize it as a syndrome
and not a defined uniform entity. No single
pathogenesis has been elucidated but the syndrome
could range from a cluster of unrelated risk factors to
a constellation of risk factors linked through a common
underlying mechanism.
In the effort to introduce the metabolic syndrome into
clinical practice, several organizations have attempted
to formulate simple criteria for its diagnosis. The first
proposal came in 1998 from a consultation group on
the definition of  diabetes for the World Health
Organization. This group emphasized insulin resistance
as the major underlying risk factor and required
evidence of insulin resistance for diagnosis19.
In 1999, the European group for the Study of Insulin
Resistance (EGIR) proposed a modification of the
WHO definition. This group used the term insulin
resistance syndrome rather than metabolic syndrome20.
In 2001, the National Cholesterol Education Program
(NCEP) Adult Treatment Panel III (ATP) introduced
alternative clinical criteria for defining the metabolic
syndrome. In so doing, the purpose of ATPIII was
to identify people at higher long-term risk for
arterosclerotic vascular disease (ASCVD) who
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Others Microalbuminuria Other features
of insulin
resistance
Table 1: Clinical diagnosis of  metabolic syndrome
TG-Triglyceride  HDL-C –High density lipoprotein IGT –Impaired glucose tolerance  IFG- Impaired fasting glucose  FBG – Fasting blood
glucose T2 DM –Type 2 Diabetes Mellitus   BMI- Body mass index  Rx- Treatment
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In 2003, the American Association of Clinical
Endocrinologists (AACE) modified ATPIII criteria to
focus on insulin resistance as the primary cause of the
metabolic risk factors. Like the EGIR, the term insulin
resistance syndrome was used 22. In 2005, the
International Diabetes Federation (IDF) published new
criteria that again modified the ATPIII definition. The
IDF writing group included several members of the
original WHO consultation group. They liked the
ATPIII criteria because of  its clinical simplicity. They
were of the opinion that abdominal obesity is highly
correlated with insulin resistance such that other more
laborious measures of insulin resistance were
unnecessary23. Most recently, efforts have been made
to harmonize the criteria proposed by the ATPIII and
the IDF consensus was that abdominal obesity should
not be a prerequisite for diagnosis rather it should be
one of the 5 criteria and the ethnic specific cut-off
values as proposed by the IDF should be adopted24.
Management of the Metabolic Syndrome
 The primary goal of clinical management in individuals
with the metabolic syndrome is to reduce risk for
arterosclerotic vascular disease. Even in people with
the metabolic syndrome, first-line therapy is directed
toward major risk factors: LDL-Cholesterol above
the target goal, hypertension, and diabetes. Prevention
of type 2 diabetes mellitus is another important goal
when it is not present in a person with the metabolic
syndrome. For individuals with established diabetes,
risk factor management must be intensified to diminish
their higher risk for arterosclerotic vascular disease. The
prime emphasis in management of the metabolic
syndrome is to mitigate the modifiable underlying risk
factors (obesity, physical inactivity, and atherogenic diet)
through lifestyle changes.
Obesity and Physical Inactivity
Weight reduction deserves first priority in individuals
with obesity and the metabolic syndrome. Both weight
reduction and maintenance of a lower weight are best
achieved by a combination of reduced caloric diet,
increased physical activity and the use of principle of
behavioral change. Medications such as phentermine,
orlistat, sibrutamine, bupropion and rimonabant may
also be of value in some patients when indicated. So
also is bariatric surgery which is being used increasingly
in the United States for severe obesity.
Increasing physical activity assists in weight reduction
and reduces overall ASCVD risk. Current
recommendations for the public call for accumulation
of greater than 30 minutes of moderate-intensity
exercise, such as brisk walking, on most, and preferably
all days of the week. Preference is given to 60 minutes
of moderate intensity brisk walking to be
supplemented by other activities. These activities include
use of  treadmill, jogging, swimming, biking, golfing,
team sports, and resistance training25-31.
Atherogenic Dyslipidemia
This condition consists of  abnormal level of
triglycerides and apoB, small LDL particles, and low
HDL-Cholesterol. LDL-Cholesterol is the primary
target for therapy while the other lipid abnormalities
are secondary. LDL-C reduction goals depend on
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Homeostatic model assessment for insulin resistance
Elevated free fatty acids
Vascular Dysregulation
Hypertension





↑ inflammatory cytokines (IL-6)
Prothrombotic States
Fibrinolytic factors (Plasminogen activator inhibitor)
Clotting factors (fibrinogen)
Others
Activation of the corticosteroid axis,
polycystic ovarian syndrome
Hyperuricemia, elevated asymmetric dimethylarginine
Non-alcoholic fatty liver/steatohepatitis,
obstructive sleep apnea
Table 2: Components of metabolic syndrome
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estimates of absolute risks as recommended by the
ATPIII of the National Cholesterol Education
Program. A related and potential secondary target is
elevated total apoB, this measure denotes the number
of atherogenic lipoprotein in the circulation. Statins
lower both LDL-C and non-HDL-C by a similar
percentage. Moreover statins reduce risk for ASCVD
events in patients with the metabolic syndrome. Both
fibrates and nicotinic acid reduce non-HDL-C and
reportedly decrease the risk for ASCVD32-34.
Systemic Hypertension
When overt hypertension is present without diabetes
or chronic kidney disease, the goal for antihypertensive
therapy is a blood pressure of  less than 140/90mmHg.
In the presence of diabetes or chronic kidney disease,
the blood pressure goal is less than 130/80mmHg.
Mild elevations of blood pressure often can be
effectively controlled with lifestyle therapies such as
weight control, increased physical activity, alcohol
moderation, sodium reduction, smoking cessation and
increased consumption of fresh fruits, vegetables and
low-fat dairy products. If  hypertension cannot be
adequately controlled by lifestyle therapies,
antihypertensive drugs usually are necessary to prevent
long-term adverse effects35. Some investigators
support angiotensin-converting enzyme (ACE)
inhibitors as first line therapy for hypertension in
metabolic syndrome, especially when either type 2
diabetes mellitus or chronic kidney disease is present.
Indeed inhibition of the rennin-angiotensin system with
ACE inhibitors or Angiotensin receptor blocker (ARBs)
may lower risk for diabetes itself36. The results of a
large clinical trial raised the possibility that use of
diuretics in patients with impaired fasting glucose or
impaired glucose tolerance may increase the likelihood
of progression to type 2 diabetes mellitus, although
diuretics do in fact lower the risk for cardiovascular
events. Most investigators in the hypertension field
believe that the potential benefit of low dose diuretics
in combination antihypertensive therapy outweighs
their risk especially in blacks37.
Insulin Resistance and Hyperglycemia
Lifestyle intervention can reduce the risk for
conversion of impaired fasting glucose (IFG) and
impaired glucose tolerance (IGT) to type 2 diabetes.
Preliminary reports indicate that metformin,
thiazolidinediones or acarbose also reduce risk of type
2 diabetes in people with IFG or IGT38, 39.
Glycemic control to a hemoglobin AIc of less than
7% will reduce microvascular complications and could
reduce the risk for macrovascular disease as well. The
use of lipid-altering, anti-hypertensive and anti-diabetic
drugs can modify insulin sensitivity and body weight.
Metformin and thiazolidinediones improve insulin
sensitivity but have discrepant effects on body weight:
metformin reduces weight while thiazolidinediones
increase it40.
Prothrombotic State
This risk factor is characterized by elevations of
fibrinogen, plasminogen activator inhibitor 1, and
possibly other coagulation factors. The only available
clinical approach to reducing an increased risk for
arterial thrombosis in patients with diabetes is to give
anti-platelet drugs. These drugs are universally
recommended unless contraindicated in patients with
established cardiovascular disease. In other people with
the metabolic syndrome, aspirin prophylaxis is a
therapeutic option when the risk for cardiovascular
disease events is judged to be relatively high41, 42.
Pro-inflammatory State
This condition can be identified by elevated cytokines
(TNFá and interleukin 6) and acute phase reactants
(C-reactive protein and fibrinogen). An elevated C-
reactive protein is widely thought to be an indicator
of a pro-inflammatory state and to be associated with
higher risk for both cardiovascular disease and diabetes.
Lifestyle therapies especially weight reduction, will
reduce concentrations of this cytokine and thus mitigate
an underlying inflammatory state. No specific anti-
inflammatory drugs are available to treat this state.
However, several drugs used to treat other metabolic
risk-factors- statins, fibrates, and thiazolidinediones-
have been reported to reduce concentrations of C-
reactive proteins43, 44.
CONCLUSION
Metabolic syndrome represents a constellation of
cardiovascular risk factors which increase the risk of
arterosclerotic cardiovascular disease and development
of  type 2 diabetes. Type 2 diabetes poses a major
public health problem world-wide with a projected
number of over 300 million people by 2025. Risk
stratification, early identification and radical intervention
will thus help in stemming the tide of this dangerous
trend.
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